UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: December 21, 2006
Date of earliest event reported: December 18, 2006
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
1-3619
13-5315170
(State or other Jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
235 East 42nd Street
New York, New York
(Address of principal executive offices)
10017
(Zip Code)
Registrant's telephone number, including area code:
(212) 573-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
Henry A. McKinnell served as an executive of Pfizer Inc.
( Pfizer ) for 36 years, beginning in 1971. He became Chief
Executive Officer in 2001, and subsequently entered into an employment
agreement with Pfizer dated as of January 1, 2001 (the Employment
Agreement ). Among other provisions pertaining to Dr. McKinnell s
compensation and conditions of service, the Employment Agreement specifies
the parties' rights and obligations upon the termination of his employment
for various reasons.
On July 28, 2006, Pfizer announced that Jeffrey B. Kindler would succeed
Dr. McKinnell as Chief Executive Officer of Pfizer effective July 31,
2006 ( Resignation Date ). At that time, it was agreed that
Dr. McKinnell would continue to serve as the Chairman of the Board of
Directors of Pfizer (the Board ) and as a Pfizer employee
through February 28, 2007 ( Termination Date ), so there would
be an orderly transition of his responsibilities. On December 18, 2006,
Dr. McKinnell resigned from his position as Chairman of the Board.
The Board s replacement of Dr. McKinnell as Chief Executive Officer
with Mr. Kindler contractually obligated Pfizer under the Employment Agreement
to provide Dr. McKinnell with certain severance payments and benefits.
In addition, Pfizer is obligated to provide Dr. McKinnell with pension
benefits under Pfizer s retirement annuity plan and supplemental
retirement annuity plan as well as distributions with respect to prior
compensation that Dr. McKinnell elected to defer under Pfizer s
supplemental savings plan and other deferred compensation plans for personal
tax-planning purposes. A major payment obligation to Dr. McKinnell is
for pension benefits with an estimated lump sum value of approximately
$82 million, which was previously disclosed in Pfizer s 2006 Definitive
Proxy Statement filed on March 16, 2006. Another major obligation is the
payment of approximately $78 million of nonqualified deferred compensation
owed to Dr. McKinnell, which will be paid in accordance with his payment
elections under such plans. This amount includes approximately $67 million
of Dr. McKinnell s own money from prior compensation that he had
earned and voluntarily elected to defer with Pfizer. Pfizer has had the
use of these funds in the business during the deferral period and has
credited Dr. McKinnell with investment returns applicable to each deferral.
No above-market or preferential earnings have been credited. This amount
also includes matching contributions to which he, like other Pfizer employees
participating in the plan, was entitled to receive under Pfizer s
supplemental savings plan.
On December 18, 2006, Pfizer entered into an agreement with Dr. McKinnell
which details the terms of his departure from Pfizer (the Agreement ).
Under the Agreement, Dr. McKinnell has agreed to step down from his position
on the Board and to retire from employment and all other positions with
Pfizer then held by him on the Termination Date. Dr. McKinnell will continue
to be paid his regular base salary, and continue to be eligible to participate
in Pfizer s employee benefit plans and programs and to receive certain
protective services from Pfizer, through the Termination Date.
The amounts and benefits payable to Dr. McKinnell as a result of his
departure as Chief Executive Officer do not exceed or are less than the
amounts and benefits that Pfizer would have been obligated to pay under
the Employment Agreement had his employment terminated without cause on
the Resignation Date. Under the Agreement, Dr. McKinnell will receive
the following payments and benefits as a result of his departure: (i)
severance of $11,941,000, payable in a single lump sum on March 15, 2007,
which equals two times the sum of his base salary and 2005 bonus, (ii)
payment on March 15, 2007 of a pro-rata bonus for 2006 in the amount of
$2,158,300, which equals his 2005 bonus prorated through the Resignation
Date, (iii) payment on March 15, 2007 of $305,644 for accrued but unused
vacation time through the Termination Date, (iv) the benefits, or payment
of $576,573 on March 15, 2007 for the nominal value of the benefits, Dr.
McKinnell would receive under Pfizer s savings plan, supplemental
savings plan and medical, dental, life insurance, long-term disability
and financial counseling programs if his employment with Pfizer had continued
for two additional years, (v) full vesting of all unvested restricted
stock and restricted stock unit awards, with a value of $5,783,156, based
on the closing price of Pfizer common stock on December 13, 2006, and
full vesting of all unvested stock options with continued exercisability
of all stock options through the expiration dates of such options, each
in accordance with their original terms and conditions (including Dr.
McKinnell s compliance with restrictions on competition, disclosure
or misuse of confidential information and engaging in certain activities
harmful to Pfizer), and (vi) continued medical and dental coverage under
Pfizer s retiree plans for himself and his partner, subject to the
terms of such plans. In addition, under the Agreement, Dr. McKinnell s
outstanding performance-contingent share and performance share awards
will be settled in accordance with the original terms and conditions of
such awards (including Dr. McKinnell s compliance with restrictions
on competition, disclosure or misuse of confidential information and engaging
in certain activities harmful to Pfizer) by the delivery of a number of
shares of common stock calculated based on Pfizer s actual performance
relative to the pharmaceutical peer group during each applicable performance
period, assuming for this purpose that Dr. McKinnell remained employed
by Pfizer through the date of payment, except that the amount of the award
for the performance periods that commenced on January 1, 2003 and January
1, 2005 and with respect to 198,000 target shares subject to the award
for the performance period that commenced on January 1, 2004 will be prorated
for the number of days during the applicable performance period Dr. McKinnell
was employed by Pfizer. If target level performance is achieved with respect
these outstanding awards, Dr. McKinnell would receive in settlement of
such awards 719,533 shares of Pfizer common stock with an aggregate value
of $18,268,943, based on the closing price of Pfizer common stock on December
13, 2006. Additional information about the terms and conditions of Dr.
McKinnell s performance-contingent share and performance share awards
is contained in Pfizer s Definitive Proxy Statement filed on March
16, 2006 and Pfizer s Form 8-K filed on February 24, 2006. Dr. McKinnell
did not and will not receive any additional grants of share or equity-based
awards after the Resignation Date.
If any payment or benefit required under the Agreement cannot be provided
or made at the specified time without incurring sanctions under Section
409A of the Internal Revenue Code, then such benefit or payment shall
be provided in full at the earliest time when such sanctions will not
be imposed. If the severance, pro-rata bonus or accrued vacation payments
described above are delayed to avoid sanctions under Section 409A, Pfizer
has agreed to pay interest at a market rate on these amounts during such
delay.
In the Agreement, Dr. McKinnell has agreed to be bound by customary confidentiality
and non-competition covenants following the Terminate Date, to provide
reasonable litigation assistance to Pfizer and its counsel following the
Terminate Date and to execute a release of claims in favor of Pfizer.
Dr. McKinnell s and Pfizer s rights and obligations under
the Employment Agreement (other than Dr. McKinnell s right to indemnification,
which survives) and the Change in Control Severance Agreement between
Pfizer and Dr. McKinnell, as amended, have been terminated as a result
of the execution of the Agreement.
Nonqualified Deferred Compensation
Dr. McKinnell will receive approximately $78 million of nonqualified
deferred compensation in accordance with Pfizer s supplemental savings
and other deferred compensation plans (excluding the supplemental retirement
annuity plan), which includes approximately $67 million of his own money
from prior compensation he had earned and voluntarily elected to defer.
Amounts deferred at the election of Dr. McKinnell were previously disclosed
in the Summary Compensation Table contained in the Proxy Statement for
the fiscal year in which earned in accordance with applicable SEC disclosure
requirements then in effect.
Set forth below is certain additional information about Dr. McKinnell s
nonqualified deferred compensation under Pfizer s supplemental savings
and other deferred compensation plans, including Pfizer s contributions,
aggregate earnings and the balance of Dr. McKinnell s account under
such plans on December 13, 2006.
Nonqualified Deferred Compensation
Program
Dr. McKinnell s Contributions
Pfizer s
Contributions
Aggregate
Earnings
Balance on
December 13, 2006
Supplemental Savings (401(k) Type) Plan(1)
$10,770,489
$2,508,029
$13,278,518
Deferred Performance-Contingent Shares (2)
$37,599,112
$4,169,977
$41,769,089
Deferred Bonuses (3)
$18,788,495
$4,073,839
$22,862,334
Totals
$67,158,096
$2,508,029
$8,243,816
$77,909,941
(1) The amounts shown reflect net contributions
and return on those contributions on December 13, 2006.
(2) Dr. McKinnell voluntarily elected to defer receipt of 1,480,863 shares
of Pfizer common stock and received 164,237 shares (the value of which
is shown in the Aggregate Earnings column) as reinvested
dividends on the deferred shares. The values shown are based on the closing
price of Pfizer common stock on December 13, 2006 ($25.39).
(3) Dr. McKinnell voluntarily elected to defer receipt of $18,788,495
of bonus amounts and has received $4,073,839 as investment income on those
deferrals. Dr. McKinnell has deferred all or a portion of nine bonus awards.
Over that period, he has earned 120% of the Federal long-term rate on
those deferrals, which averaged an annual return of 5.7%.
Pension Benefits
Dr. McKinnell is entitled to receive pension benefits under Pfizer s
retirement annuity plan and supplemental retirement annuity plan as previously
disclosed in Pfizer s Definitive Proxy Statement filed on March
16, 2006. Set forth below are the number of years of plan service, his
estimated annual pension payable on February 28, 2007, if selected, and
the estimated lump sum value of his annual pension on February 28, 2007
under these plans.
Estimated Pension Benefits
Number of Years of Plan Service
Annual Pension Payable on February 28,
2007
Lump Sum Value of Annual Pension (1)
Retirement Annuity Plan and Supplemental Retirement Annuity Plan
35
$6,646,142
$82,305,823
(1) The lump sum amount was estimated based on the current interest rate of
4.69%, which is the most recent published rate. The actual amount will be determined
based on the interest rate effective for retirements on February 28, 2007.
Additional information about the retirement annuity plan and supplemental retirement
annuity plan is contained in Pfizer s Definitive Proxy Statement filed
on March 16, 2006.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
Exhibit 10
Agreement between Pfizer Inc. and Henry A. McKinnell dated December 18,
2006.
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
By: /s/ Margaret M. Foran
Margaret M. Foran
Title: Senior Vice President-Corporate
Governance, Associate General Counsel and Corporate Secretary
Dated: December 21, 2006
EXHIBIT INDEX
Exhibit No.
Description
10
Agreement between Pfizer Inc. and Henry A. McKinnell dated December
18, 2006.